The FDA proposed a new risk-based pathway that would cut time to first-in-human trials, aiming to reduce regulatory burden and accelerate clinical development in the U.S. The plan would create an optional Investigational New Drug (IND) pathway using preclinical data that can be confirmed without animal studies. The proposal is framed as a response to shifts in global early-stage activity, including China’s efforts to move faster in initial development. The FDA’s approach is intended to lower development costs while enabling earlier Phase 1 enrollment. If implemented, the policy could alter how sponsors structure early programs—especially when animal studies are limited or when timelines are tightly constrained. Industry will also look for how the FDA defines eligible evidence thresholds and which submissions would be required for operational rollout.